News Alert: Epinephrine Nasal Spray, Dillon’s Law on Stock Epinephrine, Peanut Allergy Treatment, and More
Read below for more information about the FDA’s decision on neffy® epinephrine nasal spray, a peanut allergy vaccine clinical trial for people in Missouri and Wisconsin, a stock epinephrine law, and more.
|
|
|
Kids with Food Allergies (KFA) aims to build a safe and inclusive future for people with food allergies. We cannot accomplish this goal without understanding the things that matter most to people with food allergies and championing policies that would improve their lives. KFA’s research and advocacy projects are designed to amplify your voice and empower you to act. This newsletter is a tool to keep you updated on the latest news and ways to get involved in driving change for a better future.
Will you become a change agent by making a gift in support of our research and advocacy projects today?
|
|
|
Currently, epinephrine is only available in devices that use needles. A nasal spray would give people managing severe allergic reactions (anaphylaxis) more options. And as AAFA told the FDA earlier this year, people at risk of anaphylaxis deserve to have a choice in treatment. In an AAFA study on food allergies in 2019, nearly three out of four people reported not using or receiving a dose of epinephrine during a recent severe allergic reaction. Fear of epinephrine and needle phobia are significant reasons why people are hesitant or delay treatment for a condition that requires immediate action.
Drug safety and efficacy are important to patients and caregivers. Epinephrine itself has a long-proven safety record. The FDA has requested an additional study on epinephrine nasal spray use by people with allergic rhinitis — which could further delay neffy from getting approval by at least a year.
We hope needle-free epinephrine drug manufacturers and the FDA are able to find solutions to bring needle-free options to the market sooner rather than later. However, AAFA encourages support for the scientific process for drug development and urges participation in future clinical trials.
If you or your child have a fear of injections, read our tips on how to become more comfortable using your current treatment option for anaphylaxis.
|
|
|
Here’s more food allergy research news:
|
|
|
The following is a message from Probando
Help for Peanut Allergy? Join the PROTECT Trial.
The tongue tingles, the lips burn, the throat itches and you have difficulties breathing – Are you suffering from peanut allergy? Would you like to support researchers develop an investigational treatment to fight peanut allergy? Then this is your opportunity. Join the PROTECT trial.
Madison/Wisconsin: Healthy individuals with peanut allergy:
https://www.probando.io/#/study-listing/study-detail/741
St. Louis/Missouri: Healthy individuals with peanut allergy:
https://www.probando.io/#/study-listing/study-detail/742
|
|
|
AAFA wants to expand information about eosinophilic gastroenteritis (EGE)! Please reach out to us if you have experience with EGE and would be interested in learning more about our research opportunities.
EGE is a condition in which a type of white blood cell, the eosinophil, causes injury and inflammation to the stomach and small intestine. It is different from EoE, which causes damage to the esophagus.
|
|
|
Named after Dillion Meuller, Dillion’s Law is a bipartisan bill that will encourage states to make epinephrine widely available so people can help prevent tragedies from anaphylaxis.
“No one should die from anaphylaxis. Dillon’s Law will help save lives by creating opportunities for people to be trained and to administer life-saving epinephrine to a person who is experiencing a life-threatening anaphylactic reaction,” said Kenneth Mendez, President and CEO of AAFA. “Dillion’s Law also removes the threat of civil litigation for a good Samaritan who jumps in to administer epinephrine in an emergency. If Dillon’s Law passes, a bystander won’t have to think twice about helping someone needing immediate administration of epinephrine in an emergency.”
Watch for more information on how you can support Dillion’s Law soon.
|
|
|
Food Allergy and EoE CME Programs
Are you a health care provider who treats people with food allergies or eosinophilic esophagitis (EoE)? Don’t miss these CME programs:
At the Forefront of Food Allergies: Preventive Strategies to Improve Outcomes
Available on demand
During this two-part series, experts in allergy, immunology, and primary care discussed:
- The changing landscape of food allergy management
- Newer approaches to enhance food allergen tolerance
- The key roles of patients and their families when making therapeutic decisions
Watch on demand now.
|
|
|
Enhancing Diagnosis and Access to Treatment in EoE: What You Need to Know from Your Patients
Friday, Sept. 29 at 11 a.m. ET
Join us for a live CME program on diagnosing and managing EoE. An expert panel of gastroenterologists will:
- Provide guidance on EoE diagnosis
- Discuss the importance of asking questions to uncover adaptive behaviors
- Share details of the current treatment paradigm
Register now for the live program, or you can watch on demand later.
|
|
|
Check out our previous issue to learn how to manage the most common food allergens, ways to find safe foods, prevent food allergy reactions at school, and more.
|
|
|
|
|
